NM_004972.4:c.3060-9427C>T
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_004972.4(JAK2):c.3060-9427C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.355 in 157,228 control chromosomes in the GnomAD database, including 10,802 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.36 ( 10585 hom., cov: 30)
Exomes 𝑓: 0.26 ( 217 hom. )
Consequence
JAK2
NM_004972.4 intron
NM_004972.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 2.04
Publications
12 publications found
Genes affected
JAK2 (HGNC:6192): (Janus kinase 2) This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
IGHEP2 (HGNC:5524): (immunoglobulin heavy constant epsilon P2 (pseudogene))
INSL6 (HGNC:6089): (insulin like 6) The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.524 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.358 AC: 54298AN: 151482Hom.: 10574 Cov.: 30 show subpopulations
GnomAD3 genomes
AF:
AC:
54298
AN:
151482
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.258 AC: 1454AN: 5628Hom.: 217 Cov.: 0 AF XY: 0.263 AC XY: 802AN XY: 3052 show subpopulations
GnomAD4 exome
AF:
AC:
1454
AN:
5628
Hom.:
Cov.:
0
AF XY:
AC XY:
802
AN XY:
3052
show subpopulations
African (AFR)
AF:
AC:
25
AN:
50
American (AMR)
AF:
AC:
22
AN:
78
Ashkenazi Jewish (ASJ)
AF:
AC:
13
AN:
56
East Asian (EAS)
AF:
AC:
9
AN:
72
South Asian (SAS)
AF:
AC:
220
AN:
828
European-Finnish (FIN)
AF:
AC:
564
AN:
2054
Middle Eastern (MID)
AF:
AC:
6
AN:
22
European-Non Finnish (NFE)
AF:
AC:
540
AN:
2178
Other (OTH)
AF:
AC:
55
AN:
290
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.452
Heterozygous variant carriers
0
37
74
112
149
186
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.359 AC: 54350AN: 151600Hom.: 10585 Cov.: 30 AF XY: 0.358 AC XY: 26539AN XY: 74106 show subpopulations
GnomAD4 genome
AF:
AC:
54350
AN:
151600
Hom.:
Cov.:
30
AF XY:
AC XY:
26539
AN XY:
74106
show subpopulations
African (AFR)
AF:
AC:
21851
AN:
41218
American (AMR)
AF:
AC:
5102
AN:
15244
Ashkenazi Jewish (ASJ)
AF:
AC:
897
AN:
3468
East Asian (EAS)
AF:
AC:
1340
AN:
5146
South Asian (SAS)
AF:
AC:
1547
AN:
4802
European-Finnish (FIN)
AF:
AC:
3519
AN:
10538
Middle Eastern (MID)
AF:
AC:
67
AN:
292
European-Non Finnish (NFE)
AF:
AC:
19061
AN:
67880
Other (OTH)
AF:
AC:
705
AN:
2102
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.507
Heterozygous variant carriers
0
1658
3316
4973
6631
8289
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
506
1012
1518
2024
2530
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1106
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.